Akebia Therapeutics(AKBA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025 • Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for Vafseo • Vafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System code • Akebia to Host Conference Call at 8:00 a.m. ET on Novembe ...